

### **Amendment to the Claims**

The following listing of claims will replace all prior versions and listings of claims.

#### **Listing of Claims:**

- 1-24. (Canceled)
25. (Previously Presented) An isolated protein comprising amino acid residues 20 to 290 of SEQ ID NO:65.
26. (Previously Presented) The isolated protein of claim 25 which comprises amino acid residues 1 to 290 of SEQ ID NO:65.
27. (Previously Presented) The isolated protein of claim 25 which comprises amino acid residues 2 to 290 of SEQ ID NO:65.
28. (Previously Presented) The isolated protein of claim 25 wherein the amino acid residues are fused to a heterologous polypeptide.
29. (Previously Presented) The isolated protein of claim 28 wherein the heterologous polypeptide is the Fc domain of immunoglobulin.
30. (Previously Presented) The protein of claim 25 wherein said protein is glycosylated.
31. (Previously Presented) The protein of claim 25 wherein said protein is fused to polyethylene glycol.
32. (Previously Presented) A composition comprising the protein of claim 25 and a pharmaceutically acceptable carrier.
33. (Previously Presented) An isolated protein produced by a method comprising:
  - (a) culturing a host cell under conditions suitable to produce the protein of claim 25;
  - and
  - (b) recovering the protein of claim 25 from the host cell culture.

34. (Previously Presented) An isolated protein comprising a polypeptide sequence which is at least 90% identical to amino acid residues 20 to 290 of SEQ ID NO:65.
35. (Previously Presented) The isolated protein of claim 34 wherein said polypeptide sequence is at least 95% identical to amino acid residues 20 to 290 of SEQ ID NO:65.
36. (Previously Presented) The isolated protein of claim 34 wherein the polypeptide sequence is fused to a heterologous polypeptide.
37. (Previously Presented) The isolated protein of claim 36 wherein the heterologous polypeptide is the Fc domain of immunoglobulin.
38. (Previously Presented) The protein of claim 34 wherein said protein is glycosylated.
39. (Previously Presented) The protein of claim 34 wherein said protein is fused to polyethylene glycol.
40. (Previously Presented) A composition comprising the protein of claim 34 and a pharmaceutically acceptable carrier.
41. (Previously Presented) An isolated protein produced by a method comprising:
  - (a) culturing a host cell under conditions suitable to produce the protein of claim 34; and
  - (b) recovering the protein of claim 34 from the host cell culture.
42. (Previously Presented) An isolated protein consisting of at least 30 contiguous amino acid residues of amino acids 20 to 290 of SEQ ID NO:65.
43. (Previously Presented) The isolated protein of claim 42 which consists of at least 50 contiguous amino acid residues of amino acids 20 to 290 of SEQ ID NO:65.

44. (Previously Presented) The isolated protein of claim 42 wherein the amino acid residues are fused to a heterologous polypeptide.
45. (Previously Presented) The isolated protein of claim 44 wherein the heterologous polypeptide is the Fc domain of immunoglobulin.
46. (Previously Presented) The protein of claim 42 wherein said protein is glycosylated.
47. (Previously Presented) The protein of claim 42 wherein said protein is fused to polyethylene glycol.
48. (Previously Presented) A composition comprising the protein of claim 42 and a pharmaceutically acceptable carrier.
49. (Previously Presented) An isolated protein produced by a method comprising:
  - (a) culturing a host cell under conditions suitable to produce the protein of claim 42; and
  - (b) recovering the protein of claim 42 from the host cell culture.
50. (Previously Presented) An isolated protein comprising the amino acid sequence of the secreted portion of the polypeptide encoded by the HWBFY57 cDNA contained in ATCC™ Deposit No. 203648.
51. (Previously Presented) The isolated protein of claim 50 which comprises the amino acid sequence of the full-length polypeptide encoded by the HWBFY57 cDNA contained in ATCC™ Deposit No. 203648.
52. (Previously Presented) The isolated protein of claim 50 which comprises the amino acid sequence of the full-length polypeptide encoded by the HWBFY57 cDNA contained in ATCC™ Deposit No. 203648, excepting the N-terminal methionine.
53. (Previously Presented) The isolated protein of claim 50 wherein the amino acid sequence is fused to a heterologous polypeptide.

54. (Previously Presented) The isolated protein of claim 53 wherein the heterologous polypeptide is the Fc domain of immunoglobulin.
55. (Previously Presented) The protein of claim 50 wherein said protein is glycosylated.
56. (Previously Presented) The protein of claim 50 wherein said protein is fused to polyethylene glycol.
57. (Previously Presented) A composition comprising the protein of claim 50 and a pharmaceutically acceptable carrier.
58. (Previously Presented) An isolated protein produced by a method comprising:
  - (a) culturing a host cell under conditions suitable to produce the protein of claim 50; and
  - (b) recovering the protein of claim 50 from the host cell culture.
59. (Previously Presented) An isolated protein comprising a polypeptide sequence which is at least 90% identical to the amino acid sequence of the secreted portion of the polypeptide encoded by the HWBFY57 cDNA contained in ATCC™ Deposit No. 203648.
60. (Previously Presented) The isolated protein of claim 59 wherein said polypeptide sequence is at least 95% identical to the amino acid sequence of the secreted portion of the polypeptide encoded by the HWBFY57 cDNA contained in ATCC™ Deposit No. 203648.
61. (Previously Presented) The isolated protein of claim 59 wherein the polypeptide sequence is fused to a heterologous polypeptide.
62. (Previously Presented) The isolated protein of claim 61 wherein the heterologous polypeptide is the Fc domain of immunoglobulin.
63. (Previously Presented) The protein of claim 59 wherein said protein is glycosylated.

64. (Previously Presented) The protein of claim 59 wherein said protein is fused to polyethylene glycol.
65. (Previously Presented) A composition comprising the protein of claim 59 and a pharmaceutically acceptable carrier.
66. (Previously Presented) An isolated protein produced by a method comprising:
  - (a) culturing a host cell under conditions suitable to produce the protein of claim 59; and
  - (b) recovering the protein of claim 59 from the host cell culture.
67. (Previously Presented) An isolated protein consisting of at least 30 contiguous amino acid residues of the secreted portion of the polypeptide encoded by the HWBFY57 cDNA contained in ATCC™ Deposit No. 203648.
68. (Previously Presented) The isolated protein of claim 67 which consists of at least 50 contiguous amino acid residues of the secreted portion of the polypeptide encoded by the HWBFY57 cDNA contained in ATCC™ Deposit No. 203648.
69. (Previously Presented) The isolated protein of claim 67 wherein the amino acid residues are fused to a heterologous polypeptide.
70. (Previously Presented) The isolated protein of claim 69 wherein the heterologous polypeptide is the Fc domain of immunoglobulin.
71. (Previously Presented) The protein of claim 67 wherein said protein is glycosylated.
72. (Previously Presented) The protein of claim 67 wherein said protein is fused to polyethylene glycol.

73. (Previously Presented) A composition comprising the protein of claim 67 and a pharmaceutically acceptable carrier.
74. (Previously Presented) An isolated protein produced by a method comprising:
- (a) culturing a host cell under conditions suitable to produce the protein of claim 67;
  - and
  - (b) recovering the protein of claim 67 from the host cell culture.